It’s only fair to share… Frevecitinib CAS 1299417-07-4 MF C22H21N7O2 MW 415.4 g/mol 3-[(3S)-3-(1-methyl-2-oxo-5-pyrazolo[1,5-a]pyridin-3-ylimidazo[4,5-b]pyridin-3-yl)piperidin-1-yl]-3-oxopropanenitrile 3-{(3S)-3-[1-methyl-2-oxo-5-(pyrazolo[1,5-a]pyridin-3-yl)-1,2-dihydro-3H-imidazo[4,5-b]pyridin-3-yl]piperidin1-yl}-3-oxopropanenitrileJanus kinase inhibitor, anti-inflammatory, 5N5L287M8T, KN 002, KN-002 Single and Multiple Ascending Dose Study of KN-002 CTID: NCT05006521 Phase: Phase 1 Status: Completed Date: 2024-08-07 SYN https://patentscope.wipo.int/search/en/detail.jsf?docId=US210080653&_cid=P11-MH2U9I-58146-1 It has now been found that a drug substance disclosed in WO2011/051452, namely the compound (S)-3-(3-(1-methyl-2-oxo-5-(pyrazolo[1,5-a]pyridine-3-yl)-1H-imidazo[4,5-b]pyridine-3(2H)-yl)piperidin-1-yl)-3-oxopropanenitrile having the structure …